|
|
|
| Separation and Evaluation of Anticancer Components from Myxococcus Macrosporus STXZ54 |
| WEN Ye, TANG Shao-jun, XIAO Rong, HUANG Tong-long, LEI Liang-huan, DING Xue-zhi, XIA Li-qiu |
| State Key Laboratory Breeding Base of Microbial Molecular Biology, College of Life Science, Hunan Normal University, Changsha, Province 410081, China |
|
|
|
Abstract Myxobacteria are known to be the third category of bacteria, which produce metabolites of potential anticancer effects. Here the lab-stored Myxococcus macrosporus STXZ54 was cultured, and components of its supernatants were attained by ammonium sulfate or acetone precipitation. Cytotoxic effects of the sediments were evaluated through an in vitro method. Further, the unique protein, WGF5, was successfully separated by high performance liquid chromatography from the myxobacteria. Its inhibitory effects on cancer cells were also analyzed by MTT assay. Simultaneously, confocal microscopy was employed to observe the alterations of B16 subcellular structure after treatment by WGF5. The results demonstrated that WGF5 was a very stable protein under room temperature and could efficiently inhibit the growth of B16, Hela, MCF-7 and Hep-3B cancer cells. The IC50 of WGF5 after 48 h incubation with the cancer cells was 2.767 μg/ml, 2.204 μg/ml, 3.758 μg/ml and 3.073 μg/ml, respectively. Moreover, MTT assay and confocal microscopy observation found that WGF5 probably restrains the proliferation of the cancer cells through changing the cell morphology. Briefly, this study indicates that the WGF5 of Myxococcus macrosporus STXZ54 has an broad-spectrum anticancer effects and could be used for cancer therapy in the near future.
|
|
Received: 29 May 2014
Published: 25 September 2014
|
|
|
|
|
|
[1] Kaiser D, Warrick H. Myxococcus xanthus swarms are driven by growth and regulated by a pacemaker. Journal of Bacteriology, 2011, 193(21): 5898-5904.
[2] Gerth K, Müller R. Moderately thermophilic Myxobacteria: novel potential for the production of natural products isolation and characterization. Environmental Microbiology, 2005, 7(6): 874-880.
[3] Ringel S, Greenough R, Roemer S, et al. Ambruticin (W7783), a new antifungal antibiotic. The Journal of Antibiotics, 1977, 30(5): 371.
[4] Reichenbach H, Höfle G. Biologically active secondary metabolites from myxobacteria. Biotechnology Advances, 1993, 11(2): 219-277.
[5] 李曙光, 周秀文, 李越中等. 粘细菌的种群生态及其生存策略. 微生物学通报, 2013, 40(1): 172-179. Li SH G, Zhou X W, Li Y ZH, et al. Population ecology and survival strategy of myxobacteria. Microbiology China, 2013, 40(1): 172-179.
[6] Nan B, Zusman D R. Uncovering the mystery of gliding motility in the myxobacteria. Annual Review of Genetics, 2011, 45: 21.
[7] Schmitz A, Kehraus S, Schaberle T F, et al. Corallorazines from the Myxobacterium Corallococcus coralloides. Journal of Natural Products, 2014.
[8] Zhang L, An R, Wang J, et al. Exploring novel bioactive compounds from marine microbes. Current Opinion in Microbiology, 2005, 8(3): 276-281.
[9] Gerth K, Steinmetz H, Höfle G, et al. Chlorotonil A, a Macrolide with a Unique gem-Dichloro-1, 3-dione Functionality from Sorangium cellulosum, So ce1525. Angewandte Chemie International Edition, 2008, 47(3): 600-602.
[10] Reboll M R, Ritter B, Sasse F, et al. The myxobacterial compounds spirangien a and spirangien M522 are potent inhibitors of IL-8 expression. Chem Bio Chem, 2012, 13(3): 409-415.
[11] Weissman K J, Müller R. Myxobacterial secondary metabolites: bioactivities and modes-of-action. Natural Product Reports, 2010, 27(9): 1276-1295.
[12] Brogdon C F, Lee F Y, Canetta R M. Development of other microtubule-stabilizer families: the epothilones and their derivatives. Reactions, 2014, 22: 23.
[13] Midzak A S, Liu J, Zirkin B R, et al. Effect of myxothiazol on Leydig cell steroidogenesis: inhibition of luteinizing hormone-mediated testosterone synthesis but stimulation of basal steroidogenesis. Endocrinology, 2007, 148(6): 2583-2590.
[14] 唐少军,肖蓉,文也,等. 粘细菌STXZ54的分离鉴定及其抗肿瘤活性. 微生物学报, 2014, 54(5): 532-542. Tang SH J, Xiao R, Wen Y, et al. Isolation and identification of Myxobacteria strain STXZ54 with antitumor activities. Acta Microbiologica Sinica, 2014, 54(5): 532-542.
[15] Guo W J, Tao W Y. Phoxalone, a novel macrolide from Sorangium cellulosum: structure identification and its anti-tumor bioactivity in vitro. Biotechnology Letters, 2008, 30(2): 349-356.
[16] Plaza A, Garcia R, Bifulco G, et al. Aetheramides A and B, potent HIV-inhibitory depsipeptides from a myxobacterium of the new genus "Aetherobacter". Organic Letters, 2012, 14(11): 2854-2857.
[17] Lang E, Stackebrandt E. Emended descriptions of the genera Myxococcus and Corallococcus, typification of the species Myxococcus stipitatus and Myxococcus macrosporus and a proposal that they be represented by neotype strains. Request for an opinion. International Journal of Systematic and Evolutionary Microbiology, 2009, 59(8): 2122-2128.
[18] Wolfe A J, Mohammad M M, Cheley S, et al. Catalyzing the translocation of polypeptides through attractive interactions. Journal of the American Chemical Society, 2007, 129(45): 14034-14041.
[19] 丁玲, 董军, 肖远胜,等. 蛋白质的反相液相色谱保留方程研究. 分析化学, 2013, 41(2): 181-186. Ding L, Dong J, Xiao Y SH, et al. Study on retention equation for protein in reversed phase liquid chromatography. Chinese Journal of Analytical Chemistry, 2013, 41(2): 181-186.
[20] Shiota M, Itsumi M, Yokomizo A, et al. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer. Prostate, 2014, 74(8):829-838.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
